Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 68

1.

Could local delivery of bisphosphonates be a new therapeutic choice for hemangiomas?

Yu H, Qin A.

Med Hypotheses. 2009 Oct;73(4):495-7. doi: 10.1016/j.mehy.2009.06.015. Epub 2009 Jul 21.

PMID:
19625131
2.

Could local deliver of bisphosphonates be a new therapeutic choice for Gorham-Stout syndrome?

Sun S, Liu X, Ma B, Zhou Y, Sun H.

Med Hypotheses. 2011 Feb;76(2):237-8. doi: 10.1016/j.mehy.2010.10.006. Epub 2010 Nov 1.

PMID:
21044823
3.

Potential roles of allograft inflammatory factor-1 in the pathogenesis of hemangiomas.

Jia J, Zhao YF, Zhao JH.

Med Hypotheses. 2007;68(2):288-90. Epub 2006 Sep 28.

PMID:
17010532
4.

The potential efficacy of omega-3 fatty acids as anti-angiogenic agents in benign vascular tumors of infancy.

Sterescu AE, Rousseau-Harsany E, Farrell C, Powell J, David M, Dubois J.

Med Hypotheses. 2006;66(6):1121-4. Epub 2006 Feb 24.

PMID:
16500033
5.

Induction of apoptosis in human dermal microvascular endothelial cells and infantile hemangiomas by interferon-alpha.

Sgonc R, Fuerhapter C, Boeck G, Swerlick R, Fritsch P, Sepp N.

Int Arch Allergy Immunol. 1998 Nov;117(3):209-14.

PMID:
9831809
6.

Self-assembling nanoparticles for the release of bisphosphonates in the treatment of human cancers [WO2012042024].

Gou J, Zhang K, Tang X.

Expert Opin Ther Pat. 2012 Nov;22(11):1367-75. doi: 10.1517/13543776.2012.714371. Epub 2012 Aug 28.

PMID:
22925002
7.

Infantile hemangioma is a proliferation of LYVE-1-negative blood endothelial cells without lymphatic competence.

Nguyen VA, Kutzner H, Fürhapter C, Tzankov A, Sepp N.

Mod Pathol. 2006 Feb;19(2):291-8.

8.

[Development of delivery system of bisphosphonates for the treatment of osteoporosis].

Katsumi H, Kusamori K, Sakane T, Yamamoto A.

Yakugaku Zasshi. 2010 Sep;130(9):1129-33. Review. Japanese.

9.

Bisphosphonates: from the laboratory to the clinic and back again.

Russell RG, Rogers MJ.

Bone. 1999 Jul;25(1):97-106. Review.

PMID:
10423031
10.

Intralesional corticosteroid therapy in hemangiomas: clinical outcome in 160 cases.

Chantharatanapiboon W.

J Med Assoc Thai. 2008 Oct;91 Suppl 3:S90-6.

PMID:
19253502
11.

Exploring the anti-tumour activity of bisphosphonates in early breast cancer.

Winter MC, Holen I, Coleman RE.

Cancer Treat Rev. 2008 Aug;34(5):453-75. doi: 10.1016/j.ctrv.2008.02.004. Review.

PMID:
18423992
12.

Anti-tumor potential of bisphosphonates.

Green JR.

Med Klin (Munich). 2000 Oct 15;95 Suppl 2:23-8. Review.

PMID:
11089384
13.

Assessment of bisphosphonate activity in vitro.

Mitrofan LM, Auriola S, Mönkkönen H, Mönkkönen J.

Curr Pharm Des. 2010;16(27):2970-80. Review.

PMID:
20722618
14.

Bisphosphonates: focus on inflammation and bone loss.

Iannitti T, Rosini S, Lodi D, Frediani B, Rottigni V, Palmieri B.

Am J Ther. 2012 May;19(3):228-46. doi: 10.1097/MJT.0b013e318247148f. Review.

PMID:
22549638
15.

Self-assembly nanoparticles for the delivery of bisphosphonates into tumors.

Salzano G, Marra M, Porru M, Zappavigna S, Abbruzzese A, La Rotonda MI, Leonetti C, Caraglia M, De Rosa G.

Int J Pharm. 2011 Jan 17;403(1-2):292-7. doi: 10.1016/j.ijpharm.2010.10.046. Epub 2010 Nov 3.

PMID:
21055454
16.

Effects of two novel bisphosphonates on bone cells in vitro.

Evans CE, Braidman IP.

Bone Miner. 1994 Aug;26(2):95-107.

PMID:
7994190
17.

Insulin-like growth factor 2 and potential regulators of hemangioma growth and involution identified by large-scale expression analysis.

Ritter MR, Dorrell MI, Edmonds J, Friedlander SF, Friedlander M.

Proc Natl Acad Sci U S A. 2002 May 28;99(11):7455-60.

18.
19.

Clinical value of bisphosphonates in cancer therapy.

Lüftner D, Henschke P, Possinger K.

Anticancer Res. 2007 Jul-Aug;27(4A):1759-68. Review.

20.

In vitro and in vivo antitumor effects of bisphosphonates.

Clézardin P, Fournier P, Boissier S, Peyruchaud O.

Curr Med Chem. 2003 Jan;10(2):173-80. Review.

PMID:
12570716

Supplemental Content

Support Center